Project/Lac1/AraC Promoter/

From 2010.igem.org

Revision as of 19:44, 17 October 2010

Lac1/AraC IPTG-Inducible Promoter

Background

While the string of open reading frames lie mute within Lacto-sense, the trigger that errs it into motion upon sighting IPTG, the chosen proxy for HPV presence, is the Lac1/AraC promoter. This fusion promoter recruits elements from promoters belonging to both the Lactose and Arabinose operons to create a synthetic IPTG (or appropriate Arabinose isomer) -inducible promoter. The promoter was synthesized as described by Lutz and Bujard [1] via annealed primers (that share complementary sequences of overlap) and their subsequent elongation via PCR growth.

Derived from the naturally-occurring L-arabinose operon in E. coli, the AraC homodimer posses a specific DNA-binding domain that binds the araI sequence within the promoter [2]. AraC adhesion to this sequence contorts the promoter into a loop structure thus preventing the RNA polymerase from binding and initiating transcription. In the presence of arabinose, or a suitably-similar isomer, AraC undergoes a conformational shift thus altering its DNA binding domain and allowing RNA polymerase to bind the promoter. However, in the case of our synthetic inducible promoter, the araI sequence has been strategically placed adjacently upstream of the -33 hexamer that has been flagged as a RNA polymerase binding site. In the absence of arabinose, AraC-araI adhesion will impede RNA polymerase binding thus inhibiting transcription. The conformational alteration in the presence of arabinose, or an isomer, will ‘free’ AraC from its sequence and allow transcription to occur.

IPTG - isopropyl-β-D-1-thiogalactopyranoside - is an isomer of β-galactosidase that is structurally proximal enough to arabinose so as to induce the required conformational shift in AraC and hence induce transcription. Furthermore, due to the presence of the sulfur atom on the ring structure, IPTG is unable to be catabolised by the cell and thus remains at a constant concentration [3]. Due to this inherent latency of IPTG, the positive pressure that it exerts on transcription remains constant. Thus, addition of exogenous Arabinose or IPTG will induce polymerase engagement with the promoter and subsequent transcription of the downstream open reading frames. Due to the duality in activation of both Arabinose and IPTG, promoter activity can be activated to differing degrees by the selective addition of either or both inducers and hence activity can be finely regulated via appropriate dose administration.

Sequence Developement and Annotation

Specific forward and reverse primers were ordered from Inqaba Biotech that shared a 17bp region overlap so as to ensure appropriate annealing to one another.

Once annealed to one another, the primers are extended by 10 rounds of PCR so as to yield the full double-stranded promoter sequence.

Due to the activity of Taq polymerase, each of the (now complete) primers posses a single adenine overhang on their 3’ end. The pTZ57R Fermentas TA cloning vector possesses a complementary single thymine overhang in its multiple cloning site. This facilitates the insertion and ligation of the promoter fragment into the vector.

The Lac1/AraC promoter (below) as submitted to The Registry in the Standard Assembly PSB1C3 plasmid backbone (exhibiting chloramphenicol resistance) with appropriate annotations of Standard Assembly restriction sites as well as key plasmid features. Illustration courtesy Dr Marco Weinberg [4].

Testing and Validation

References

[1] Lutz R. & Bujard H. (1997), Independent and tight regulation of transcriptional units in Escherchia coli via the LacR/O, the TetR/O and AraC/I_1- I_2 regulatory elements. Nucleic Acids Research 25: 1203-1210.
[2] Schleif R. (2000), Regulation of the L-arabinose operon in Escherichia coli. Trends in Genetics 16: 559-565.
[3] Hansen L.S., Knudsen S. & Sorensen S.J. (1998), The Effect of the lacY Gene on the Induction of IPTG Inducible Promoters, Studies in Escherichia coli and Pseudomonas fluorescens. Current Microbiology 36: 341-347.
[4] Marco Weinberg, PhD. Antiviral Gene Therapy Research Unit, Department of Molecular Medicine and Haematology, University of the Witwatersrand Medical School, 7 York Rd. Parktown 2193 SOUTH AFRICA, marc.weinberg@wits.ac.za.